Posted by Michael Wonder on 03 May 2023
Ripretinib for treating advanced gastro-intestinal stromal tumour after three or more treatments
3 May 2023 - NICE has issued evidence-based recommendations on ripretinib (Qinlock) for treating gastrointestinal stromal tumour in adults after 3 or more treatments.
Ripretinib is not recommended, within its marketing authorisation, for treating advanced gastrointestinal stromal tumour (GIST) in adults after 3 or more kinase inhibitors, including imatinib.
